A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With EGFR Exon 19 Deletion Identified via Liquid Genomic Profiling
In Vivo · 2025
DOI: 10.21873/invivo.14164 ↗Kurz gefasst
Fallbericht in der Zeitschrift In Vivo, 2025. Verfasst von Yohei Fukuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Training Center, International Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Exons, Adenocarcinoma of Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Mixed histological lung cancers, such as combined small-cell carcinoma (SCLC) and adenocarcinoma, are rare and often present diagnostic and therapeutic challenges due to intratumoral heterogeneity. In such cases, conventional tissue biopsies may fail to detect key genetic alterations, especially when sampling is limited or affected by tumor evolution. Liquid biopsy has emerged as a complementary approach capable of capturing broader genomic information in a non-invasive manner. CASE REPORT: We describe a 73-year-old woman with metastatic lung cancer initially diagnosed as EGFR wild-type adenocarcinoma via tissue biopsy. The patient underwent multiple lines of therapy, including immune checkpoint inhibitors and cytotoxic chemotherapy. Over time, the histology shifted, and repeat biopsy identified small-cell carcinoma. Due to the tumor's evolving nature and limited biopsy accessibility, a liquid biopsy using FoundationOne Liquid CDx was performed. This identified an EGFR exon 19 deletion (T751_A755del) that had not been detected in prior tissue analyses. Targeted therapy with osimertinib was initiated as fifth-line treatment, resulting in temporary disease stabilization and reduction in tumor markers. CONCLUSION: This case illustrates the clinical value of liquid biopsy in detecting actionable mutations in patients with mixed histological lung cancers where tissue-based testing is inconclusive. Liquid biopsy enabled a personalized therapeutic approach without the need for further invasive procedures. Such strategies may be essential in managing histologically and genomically heterogeneous tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Training Center, International Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan hkosuke@saitama-med.ac.jp.
Zitieren
APA
Fukuda, Y., Hashimoto, K., Kaira, K., Mouri, A., Ishii, R., Hashimoto, N., Miura, Y. U., Shiono, A., Yamaguchi, O. U., Imai, H., & Kagamu, H. (2025). A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With EGFR Exon 19 Deletion Identified via Liquid Genomic Profiling. In Vivo. https://doi.org/10.21873/invivo.14164
Vancouver
Fukuda Y, Hashimoto K, Kaira K, Mouri A, Ishii R, Hashimoto N, et al. A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With EGFR Exon 19 Deletion Identified via Liquid Genomic Profiling. In Vivo. 2025. doi:10.21873/invivo.14164
BibTeX
@article{Fukuda2025,
author = {Fukuda, Yohei and Hashimoto, Kosuke and Kaira, Kyoichi and Mouri, Atsuto and Ishii, Reina and Hashimoto, Naohito and Miura, Y U and Shiono, Ayako and Yamaguchi, O U and Imai, Hisao and Kagamu, Hiroshi},
title = {A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With EGFR Exon 19 Deletion Identified via Liquid Genomic Profiling},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14164}
}
EUVIMED